Characteristics of the 3 subgroups of patients with SLE. Values are n (%).
| Characteristics | ASA + HCQ > 600 g, n = 85 | ASA + HCQ < 600 g or no HCQ, n = 79 | HCQ Alone, n = 19 | p* |
|---|---|---|---|---|
| Hypercholesterolemia | 11 (12.9) | 13 (16.4) | 1 (5.2) | 0.428 |
| Hypertriglyceridemia | 9 (10.5) | 9 (11.3) | 1(5.2) | 0.731 |
| Hypertension | 17 (20) | 24 (30.3) | 8 (42.1) | 0.091 |
| Diabetes | 4 (4.7) | 3 (3.7) | 1 (5.2) | 0.941 |
| Obesity | 6 (7) | 7 (8.8) | 1 (5.2) | 0.835 |
| aPL positivity | 25 (29.4) | 23 (29.1) | 3 (15.7) | 0.462 |
| Ever smokers | 43 (50.5) | 30 (37.9) | 7 (36.8) | 0.217 |
| Severe SLE | 52 (61.1) | 50 (63.2) | 11 (57) | 0.899 |
| High-dose steroids, cumulative dose prednisone equivalent > 40 g | 23 (27) | 22 (27.8) | 6 (31.5) | 0.924 |
| Statins | 10 (11.7) | 9 (11.3) | 1 (5.2) | 0.702 |
| Basal SDI ≥ 1 | 11 (12.9) | 18 (22.7) | 2 (10.5) | 0.179 |
| Basal SELENA-SLEDAI ≥ 6 | 56 (65.8) | 53 (67) | 11 (57.8) | 0.748 |
↵* None of the p values are significant (significant p < 0.05). SLE: systemic lupus erythematosus; ASA: low-dose aspirin; HCQ: hydroxychloroquine; HCQ > 600 g: cumulative HCQ dose > 600 g; HCQ < 600 g: cumulative HCQ dose < 600 g; aPL: antiphospholipid antibodies; SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SELENA: Safety of Estrogens in Lupus Erythematosus National Assessment; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index.